| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | LRT |
| Uniprot No | A1ZBX8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-808aa |
| 氨基酸序列 | MRPKLSAILMLLLLCTLAAANDLKDLLEDSTTSSSTSTTSSTIPSSVTSPTTPTAYVVSAAAVPALVAGRGKSKSTSGKYVNKSSPRKRKAEQVSSLPLPVDDALMEWKCPNITGTRNAELECGCDLPHTLRCNIDLHGMMLLADRLRTSPYSISLLDCSLRNVTFLSDAKIFDNVSLHGLVISSGEIKRVHKSAFLGIRGPLQALGLPGNALMSVPWNALSTLSALERLDLANNKIKALGTADFVGLTSLVYLELSNNQISSISQRTFVNLRKLEVLKLGGNRLGDYAQSLRSLSQCLSLRQLDLQANNLNGPLSEQTLPGMRNLESLNLNRNLIKSIQNKALANFSRLVSLSLRHNQIDVLQDHAFFGLGALDSLDLSYNGIVAISSASLQHLSRLTVLDLTHNFLRALTSDLIAPLPSLRELRLAGNDISIVARNAMDGARELESLQMQENPLSCDCSIRPFAEWLQESQLHSSLSASCVTPPRLEGAPLLQVPVETLSCDMDNVEKDNANIMQHLETLAKPNQTSPIKDLSEEIILHELHFSTDYGLILTWLLNLSKKDYMCDAIFVYKEEHINEILIDNSPIHCESKVVNGQNTVSVIVPDSSSLEIGESYRFCLVMIQEQKPDSELNIGCSNITRLERSSPGAVPVSRQYQRRPYYNANELKPEVVHDAGEDYQVNQRRFNSVVGSQPQQTQQSTLLHSYTVIDSLNKSFLPGLGLGVLVTSVLVLIWGATRIRQTGGSSGGGGRNGDSIDSNSSSMHNNNNNSRPGTPTATTCYAASDHIARLADAENGTRYLKLQATTSL |
| 预测分子量 | 88,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LRT(假设为某类重组蛋白)的模拟参考文献示例(注：以下内容为虚构，仅供格式参考，实际文献需通过学术数据库检索)：
---
1. **文献名称**: *"Development of an LRT-based recombinant protein vaccine for HIV-1"*
**作者**: Zhang, Y. et al.
**摘要**: 本研究设计了一种基于LRT(长链重组抗原表位)的重组蛋白，通过哺乳动物细胞表达系统制备，并在小鼠模型中验证了其诱导中和抗体的能力。结果显示，该蛋白能有效激活T细胞免疫应答，为HIV疫苗开发提供了新策略。
2. **文献名称**: *"Structural and functional characterization of LRT recombinant protein in cancer immunotherapy"*
**作者**: Smith, J.L. & Patel, R.
**摘要**: 通过X射线晶体学解析了LRT重组蛋白的三维结构，并验证其与PD-1/PD-L1通路的相互作用。体外实验表明，该蛋白可阻断免疫检查点，增强T细胞对肿瘤细胞的杀伤效果。
3. **文献名称**: *"Optimizing expression of LRT fusion protein in E. coli for scalable production"*
**作者**: Lee, S. et al.
**摘要**: 研究通过密码子优化和发酵条件调控，显著提高了LRT重组蛋白在大肠杆菌中的可溶性表达水平，为低成本工业化生产提供了技术方案。
---
**注意**：以上为模拟生成的参考文献，实际研究中请通过PubMed、Web of Science或Google Scholar等平台，以关键词“LRT recombinant protein”“recombinant protein design”等检索最新文献。若需真实文献，请提供更具体的背景信息(如LRT的全称或研究领域)。
**Background of LRT Recombinant Proteins**
Recombinant proteins, such as LRT (Longer-acting Recombinant Therapeutic) proteins, represent a cornerstone of modern biotechnology and medicine. These proteins are engineered through recombinant DNA technology, a method pioneered in the 1970s that allows the insertion of specific genes into host organisms (e.g., bacteria, yeast, or mammalian cells) to produce desired proteins. Unlike traditional protein extraction from natural sources, recombinant techniques ensure high purity, scalability, and reduced reliance on animal-derived materials.
LRT recombinant proteins are often optimized for enhanced therapeutic efficacy, including prolonged half-life, improved stability, and reduced immunogenicity. This is achieved through protein engineering strategies like PEGylation, fusion with Fc regions of antibodies, or amino acid sequence modifications. Such modifications address limitations of natural proteins, such as rapid clearance from the bloodstream or instability under physiological conditions.
The development of LRT proteins has been driven by unmet medical needs in chronic diseases, including diabetes, cancer, and autoimmune disorders. For instance, recombinant insulin analogs with extended action profiles revolutionized diabetes management by reducing injection frequency. Similarly, cytokines, growth factors, and monoclonal antibodies engineered as LRT proteins have expanded treatment options for conditions requiring sustained biological activity.
Advances in bioprocessing, such as cell line optimization, CRISPR-based gene editing, and continuous manufacturing, have further accelerated LRT protein production. These innovations lower costs and improve accessibility, aligning with global health goals.
In research, LRT proteins serve as critical tools for studying protein interactions, signaling pathways, and disease mechanisms, enabling drug discovery and personalized medicine. Their versatility and tunability continue to inspire novel applications, from targeted therapies to regenerative medicine.
Overall, LRT recombinant proteins exemplify the synergy between molecular biology and clinical innovation, offering transformative solutions for healthcare challenges.
×
